Checkpoint Therapeutics News

HC Wainwright & Co. : Checkpoint Therapeutics (CKPT.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $34.00.

HC Wainwright & Co. : Checkpoint Therapeutics (CKPT.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $34.00.

Zhitong FinanceMay 16 10:40

Buy Rating Affirmed for Checkpoint Therapeutics Despite FDA Setback: Solid Clinical Data Fuels Optimism for 2024 Market Entry

TipRanksMay 16 09:15

Checkpoint Therapeutics: Key Governance and Growth Decisions Approved

TipRanksMay 14 06:42

Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, taking place on Monday, May 20, 2024, at 12:30 p.m. ET. Checkpoint will also attend in-person one-on-one meetings during the conference.

Fortress Biotech Inc Series A PMay 12 23:00

Checkpoint Therapeutics First Quarter 2024 Earnings: US$0.32 Loss per Share (Vs US$0.89 Loss in 1Q 2023)

Yahoo FinanceMay 12 08:54

Checkpoint Therapeutics | 10-Q: Quarterly report

SEC announcementMay 10 15:24 · Announcements

Checkpoint Therapeutics (CKPT.US): The 2024 Q1 financial report achieved revenue of $0, previous value of USD 35,000, expected value of USD 10,000; earnings per share were -0.33 USD, previous value was -0.89 USD, and expected value was -0.27 USD.

Checkpoint Therapeutics (CKPT.US): The 2024 Q1 financial report achieved revenue of $0, previous value of USD 35,000, expected value of USD 10,000; earnings per share were -0.33 USD, previous value was -0.89 USD, and expected value was -0.27 USD.

Zhitong FinanceMay 10 08:50

Checkpoint Therapeutics Q1 EPS $(0.33) Misses $(0.27) Estimate

Checkpoint Therapeutics (NASDAQ:CKPT) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.27) by 22.22 percent. This is a 62.92 percent increase over loss

BenzingaMay 10 07:33

Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates

WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first

GlobeNewswireMay 10 07:30

Checkpoint Therapeutics 1Q Loss/Shr 33c >CKPT

Checkpoint Therapeutics 1Q Loss/Shr 33c >CKPT

Dow JonesMay 10 07:30

Checkpoint Therapeutics 1Q Loss $10.9M >CKPT

Checkpoint Therapeutics 1Q Loss $10.9M >CKPT

Dow JonesMay 10 07:30

Checkpoint Therapeutics Full Year 2023 Earnings: Misses Expectations

Yahoo FinanceMar 24 08:11

HC Wainwright & Co. Reiterates Buy on Checkpoint Therapeutics, Maintains $34 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Checkpoint Therapeutics with a Buy and maintains $34 price target.

Analyst UpgradesMar 22 13:11

Checkpoint Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/22/2024 1643.59% HC Wainwright & Co. → $34 Reiterates Buy → Buy 12/20/2023 105.13% B. Riley Securities

BenzingaMar 22 13:09

Analysts' Top Healthcare Picks: Milestone Pharmaceuticals (MIST), Checkpoint Therapeutics (CKPT)

TipRanksMar 22 11:30

Checkpoint Therapeutics GAAP EPS of -$3.17 Misses by $0.49, Revenue of $0.1M Misses by $0.02M

Seeking AlphaMar 22 08:05

Checkpoint Therapeutics FY23 EPS $(3.17) Vs $(7.09) YoY; As Of December 31, 2023, Checkpoint's Cash And Cash Equivalents Totaled $4.9M

Financial Results:Cash Position: As of December 31, 2023, Checkpoint's cash and cash equivalents totaled $4.9 million, compared to $12.1 million at December 31, 2022, a decrease of $7.2 million. This

BenzingaMar 22 07:38

Checkpoint Therapeutics: Targeting FDA Resubmission for Cosibelimab by Mid-Year >CKPT

Checkpoint Therapeutics: Targeting FDA Resubmission for Cosibelimab by Mid-Year >CKPT

Dow JonesMar 22 07:32

Checkpoint Therapeutics 2023 Loss $51.8M >CKPT

Checkpoint Therapeutics 2023 Loss $51.8M >CKPT

Dow JonesMar 22 07:31

Press Release: Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasda

Dow JonesMar 22 07:30